18:48 , Mar 26, 2019 |  BC Extra  |  Financial News

NGM could get $975M valuation in NASDAQ IPO

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
20:50 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture and mouse studies identified two USP10 inhibitors that could help treat AML harboring internal tandem duplication (ITD) mutations in FLT3 . Screening of deubiquitinating enzyme...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Crenolanib regulatory update

Arog said FDA granted Fast Track designation to crenolanib besylate to treat unresectable or metastatic gastrointestinal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) D824V mutation. Crenolanib besylate is in Phase III testing...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) Studies in mice and human samples suggest inhibiting PDGFRB could help prevent pancreatic cancer...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

Arog, Pfizer deal

Pfizer granted newco Arog exclusive, worldwide rights to small molecule platelet derived growth factor receptor (PDGFR) inhibitors plarotinib ( CP-868596 ) and CP-673451. Arog renamed the compounds ARO-002 and ARO-001, respectively. Arog plans to start...